Front Pharmacol:中药复方丹参白疕消对咪喹莫特所致小鼠银屑病样炎症的改善作用

2022-04-27 紫菀款冬 MedSci原创

评估丹参白疕消的抗银屑病作用,并探讨其在咪喹莫特诱导的银屑病样小鼠模型中的潜在机制。

背景:丹参白疕消(DB)由15种中药成分组成的中药复方(见下表),在武汉市中西医结合医院治疗银屑病已有30多年的历史。虽然DB在临床中表现出良好的疗效,但其药理作用和潜在机制尚不清楚。

目的:评估DB的抗银屑病作用,并探讨其在咪喹莫特(IMQ)诱导的银屑病样小鼠模型中的潜在机制。

方法:60只雄性C57BL/6小鼠随机分为6组(n=10)——正常对照组(NC)、模型组(IMQ组)、甲氨蝶呤(MTX)治疗组,以及DB低、中、高剂量三组。除NC组外,其余5组均在背部皮肤上每日涂抹IMQ乳霜80mg,连续14天。第15天,小鼠吸入乙醚麻醉后处死,取血样和背部皮肤组织。

采用银屑病面积和严重程度指数(PASI)评价皮肤炎症的严重程度;采用HE染色评价组织学变化;ELISA检测血清中TNF-α、IL-17A、IL-23、IL-6、IL-1β、IL-22等炎症因子水平PCR检测IL-17A、IL-23、IL-6、IL-22 mRNA表达。western blotting (WB)检测NF-κB、STAT3、MAPKs信号通路相关蛋白表达水平。

结果:DB能明显改善IMQ诱导的小鼠银屑病症状。血清炎性细胞因子(TNF-α、IL-17A、IL-23、IL-6、IL-1β、IL-22)水平降低,皮肤组织中IL-17A、IL-23、IL-6、IL-22 mRNA表达下调。WB分析显示,DB可抑制NF-κB、STAT3和MAPKs信号通路的活化

结论:该研究证实了DB对IMQ诱导的银屑病样小鼠的抗银屑病活性。其机制可能与调节IL-23/TH-17轴的活性,抑制NF-κB、STAT3和MAPKs信号通路的激活有关。

 

文献来源:

Jin X, Xu H, Huang C, et al. A Traditional Chinese Medicine Formula Danshen Baibixiao Ameliorates Imiquimod-Induced Psoriasis-Like Inflammation in Mice. Front Pharmacol. 2021;12:749626. Published 2021 Dec 3. doi:10.3389/fphar.2021.749626

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1788470, encodeId=48e61e884707d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Dec 30 15:32:34 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787790, encodeId=f6d41e8779068, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jul 22 06:32:34 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996469, encodeId=f162199646912, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 25 06:32:34 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908699, encodeId=32ee19086999a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 10 04:32:34 CST 2022, time=2022-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995387, encodeId=44ee199538e44, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Mar 02 21:32:34 CST 2023, time=2023-03-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1788470, encodeId=48e61e884707d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Dec 30 15:32:34 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787790, encodeId=f6d41e8779068, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jul 22 06:32:34 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996469, encodeId=f162199646912, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 25 06:32:34 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908699, encodeId=32ee19086999a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 10 04:32:34 CST 2022, time=2022-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995387, encodeId=44ee199538e44, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Mar 02 21:32:34 CST 2023, time=2023-03-02, status=1, ipAttribution=)]
    2022-07-22 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1788470, encodeId=48e61e884707d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Dec 30 15:32:34 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787790, encodeId=f6d41e8779068, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jul 22 06:32:34 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996469, encodeId=f162199646912, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 25 06:32:34 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908699, encodeId=32ee19086999a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 10 04:32:34 CST 2022, time=2022-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995387, encodeId=44ee199538e44, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Mar 02 21:32:34 CST 2023, time=2023-03-02, status=1, ipAttribution=)]
    2022-11-25 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1788470, encodeId=48e61e884707d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Dec 30 15:32:34 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787790, encodeId=f6d41e8779068, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jul 22 06:32:34 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996469, encodeId=f162199646912, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 25 06:32:34 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908699, encodeId=32ee19086999a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 10 04:32:34 CST 2022, time=2022-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995387, encodeId=44ee199538e44, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Mar 02 21:32:34 CST 2023, time=2023-03-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1788470, encodeId=48e61e884707d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Dec 30 15:32:34 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787790, encodeId=f6d41e8779068, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jul 22 06:32:34 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996469, encodeId=f162199646912, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 25 06:32:34 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908699, encodeId=32ee19086999a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 10 04:32:34 CST 2022, time=2022-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995387, encodeId=44ee199538e44, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Mar 02 21:32:34 CST 2023, time=2023-03-02, status=1, ipAttribution=)]

相关资讯

Blood:全身炎症反应过程中诱导吞噬细胞耐受的信号机制

吞噬细胞对外源性和内源性刺激的炎症反应受到严格的调控。这种调节在全身炎症反应综合征(SIRS)中具有重要作用。在SIRS中,吞噬细胞最初会发生一种超炎症反应,随后转为一种次级的低反应状态,即所谓的耐受。这种低反应性可由Toll样受体4 (TLR4)的内毒素刺激引起,从而在以后的再刺激条件下改善反应。这种炎症反应模式的调整被称为固有免疫记忆。

Circulation:全国不同医院先天性心脏手术预后对比

中国新血管疾病现有患者达到3.3亿人。手术治疗是部分心脏病的主要治疗方式,不同医院的手术水平残次不齐。本研究旨在评估不同医院间的病例组合校正的手术死亡率、主要并发症和术后住院时间。

耐药性晚期癌症如何治疗?靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验

Kitov是一家临床阶段的生物技术公司,致力于克服肿瘤的免疫逃逸和耐药性。

FDA批准STAT3抑制剂WP1066治疗小儿脑癌试验的IND

WPD是一家临床阶段制药公司,今日宣布,美国FDA批准了STAT3抑制剂WP1066治疗小儿复发性或难治性恶性脑肿瘤的研究性新药(IND)申请,以开展I期临床试验,该试验将在亚特兰大儿童保健中心进行。

Blood:Cirmtuzumab的抗慢性淋巴细胞白血病机制!

将Nurse样细胞(NLC)与慢性淋巴细胞白血病(CLL)细胞共培养,可诱导白血病细胞的STAT3磷酸化(pSTAT3),该过程可被抗Wnt5a抗体或抗ROR1 mAb cirmtuzumab阻断。研究表明Wnt5a可在30min内诱导NF-κB活化,但需要3个多小时来诱导pSTAT3。

Cell Death Dis:BECN1在结直肠癌转移中的作用及潜在机制

细胞自噬是一种涉及捕获、降解和回收溶酶体中的细胞内蛋白和细胞器的促生存反应。癌症中细胞自噬作用的增强能够促进肿瘤微环境中癌细胞的存活率,促进癌细胞的生长和侵袭能力。